SEC Form 4 · accession 0001209191-18-039022
NEUROCRINE BIOSCIENCES INC · NBIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dimitri E. Grigoriadis
Officer — Chief Research Officer
Period of report
Jun 20, 2018
Accepted (ET)
Jun 21, 2018 · 6:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000914475
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 20, 2018 | M | 23,000 | $19.59 | A | 105,942 | D | |
| Common Stock | Jun 20, 2018 | S | 23,000 | $105.00 | D | 82,942 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock OptionF2 | $19.59 | Jun 20, 2018 | M | 23,000 | D | — | Jan 16, 2024 | Common Stock | 23,000 | 23,022 | D |
Explanation of responses
- F1The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- F2Represents option which vested 1/4 upon anniversary of grant (1/16/2015), thereafter vested in equal monthly installments over the following three years such that the entire award was fully vested at 12/16/2017.